Phase II, Randomized, Placebo-Controlled Study of Dovitinib in Combination with Fulvestrant in Postmenopausal Patients with HR2-positive, HER2-negative Breast Cancer That Had Progressed During or After Prior Endocrine Therapy
Dovitinib in combination with fulvestrant showed promising clinical activity in a FGF pathway-amplified subgroup. However, the data reported from this study should be interpreted with caution, given that fewer progression-free survival events occurred in the FGF pathway-amplified patients than was expected.
Breast Cancer Res
In The News
In The Literature